Jump to content

20250230245. Fusion Poly (ADLAI NORTYE BIOPHARMA ., .)

From WikiPatents

A FUSION POLYPEPTIDE AND ITS USE

Abstract: the present application relates to a fusion polypeptide and its use. specifically, the fusion polypeptide of the present application can block pd-1/pd-l1 signaling and/or can have the function of activating an immune response. the application also provides the use of the polypeptide.

Inventor(s): Nanhai HE, Youping WANG, Wenjing YANG, Wanwan CHEN

CPC Classification: C07K16/2827 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250230245


Cookies help us deliver our services. By using our services, you agree to our use of cookies.